Prostate Specific Antigen News and Research

RSS

Newly discovered epidermal growth factor receptor active in human pancreatic cancers

Finally some promising news about pancreatic cancer, one of the most fatal cancers, due to the difficulties of early detection and the lack of effective therapies: Johns Hopkins University pathologist Akhilesh Pandey has identified an epidermal growth factor receptor aberrantly active in approximately a third of the 250 human pancreatic cancers studied.

20 Apr 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

12 Apr 2009

Experimental drug lowers PSA levels

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels – a marker for tumor growth – in men with advanced prostate cancer for whom traditional treatment options have failed.

9 Apr 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

8 Apr 2009

Prostate screening may have benefits

Cancer Research UK scientists have shown that screening for prostate cancer using prostate specific antigen (PSA) would lead to a substantial number of tumours diagnosed at an earlier and more treatable stage.

1 Apr 2009

Nanoparticles open door to cancer prevention

Perhaps the best way to fight cancer is to prevent it from developing in the first place, and based on newly published research from investigators at the University of Wisconsin-Madison, nanoparticles may be able to make cancer chemoprevention a reality.

26 Mar 2009

New approach to prostate cancer detection - Sarcosine may distinguish between slow-growing and aggressive prostate cancers

On Friday 20 March, US researcher Dr. Chris Beecher from the University of Michigan gave a well attended lecture about sarcosine, an N-methyl derivative of the amino acid glycine, at the 24th Annual EAU Congress in Stockholm, Sweden.

25 Mar 2009

More cancer patients cured according to new data on cancer survival in Europe

New data and analyses from a long-running study of cancer survival in Europe have shown that the number of people actually cured of cancer - rather than just surviving for at least five years after diagnosis - is rising steadily.

23 Mar 2009

Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment

Metabolites are molecular fingerprints of what your cells are up to and Dr. Arun Sreekumar wants to know the impression made by cancer.

23 Mar 2009

Prostate cancer expert say keep screening in face of contradicting data

New data evaluating the impact of screening on mortality provides mixed messages on the value of prostate cancer screening.

20 Mar 2009

Selected men with low-risk prostate cancer have good clinical outcomes without immediate treatment

A multi-center study of prostate cancer patients appearing in today's Journal of Urology recommends that for some men diagnosed with low-risk prostate cancer, opting not to initially receive treatment can be safe if they are closely monitored.

16 Mar 2009

Male lumpectomy - first line treatment for prostate cancer

The so-called "male lumpectomy" - a minimally invasive interventional radiology treatment for prostate cancer - is as effective as surgery in destroying diseased tumors and can be considered a first-line treatment for patients of all risk levels and particularly those who have failed radiation, according to studies released at the Society of Interventional Radiology's 34th Annual Scientific Meeting.

10 Mar 2009

Medivation announces new positive efficacy data from trial of MDV3100 in Castration-resistant prostate cancer

Medivation, Inc. has announced the presentation of new efficacy and safety data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (CRPC) patients.

25 Feb 2009

When should PSA testing be stopped?

Although widespread Prostate-Specific-Antigen (PSA) testing has undoubtedly decreased prostate cancer mortality, is there a point of diminishing returns?

22 Feb 2009

PSA testing may be unnecessary for some older men

Certain men age 75 to 80 are unlikely to benefit from routine prostate specific antigen (PSA) testing, according to a Johns Hopkins study published in the April 2009 issue of The Journal of Urology.

22 Feb 2009

Discovery of metabolite linked to aggressive prostate cancer

Researchers from the University of Michigan Comprehensive Cancer Center have identified a panel of small molecules, or metabolites, that appear to indicate aggressive prostate cancer.

15 Feb 2009

New evidence suggests preventive effect of herbal supplement in prostate cancer

DHEA is a natural circulating hormone and the body's production of it decreases with age.

12 Jan 2009

Prostate cancer discovered in 40% of men who test negative for the disease

Forty percent of men with prostate cancer may not even know they have it, according to a new research study by the Prostate Cancer Foundation of Chicago.

16 Dec 2008

USA's largest ever prostate cancer screening program shows high compliance and consistent results

Just under five per cent of the men who took part in the prostate cancer element of the USA's largest ever cancer screening trial were diagnosed with the disease and the majority of those were picked up by screening programmes, according to research published in the December issue of the urology journal BJU International .

15 Dec 2008